The American Journal of Managed Care November 2008
Cost-Effectiveness of Insulin Analogs
Insulin analogs offer an improved balance between glycemic control and the risk of hypoglycemia, with the resultant potential to reduce the costs of treatment of hypoglycemia, hospitalization, and chronic complications. This better tolerability of analogs and the ease of administration offered by insulin pen devices can help to overcome some of the barriers to insulin use in patients with type 2 DM. Prompt initiation or intensification of insulin therapy in type 2 DM and adherence to an insulin regimen will save costs by delaying or preventing DM complications. Pharmacoeconomic models and retrospective analyses of healthcare databases have consistently shown that treatment with insulin analogs is cost-effective versus other options in the long run. Therefore, the use of insulin analogs in type 1 and type 2 DM is an appropriate investment of healthcare dollars. This review shows that validation of these potential benefits through real-world data analysis is warranted.
Author Affiliations: From the Outcomes Research Center (DIB, CM-M), University of Utah, Salt Lake City.
Funding Source: Novo Nordisk Inc provided an unrestricted educational grant for the preparation of this article. Editorial assistance was provided by Watermeadow Medical.
Author Disclosure: Dr Brixner reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article. Dr McAdam-Marx reports serving on the Managed Care Advisory Board for Novo Nordisk Inc.
Authorship Information: Concept and design (DIB, CM-M); analysis and interpretation of data (DIB, CM-M); drafting of the manuscript (CM-M); and critical revision of the manuscript for important intellectual content (DIB, CM-M).
Address correspondence to: Diana I. Brixner, PhD, RPh, Outcomes Research Center, University of Utah, 421 Wakara Way, Ste 208, Salt Lake City, UT 84108. E-mail: firstname.lastname@example.org. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31(3):596-615.
2. Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care. 2002;25(3):476-481.
3. Writing Team for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287(19):2563-2569.
4. Writing Team for the DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159-2167.
5. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602]. Lancet. 1998;352(9131):837-853.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
7. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2007;30(suppl 1):S4-S41.
8. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
9. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17-20.
10. Greisinger AJ, Balkrishnan R, Shenolikar RA, Wehmanen OA, Muhammad S, Champion PK. Diabetes care management participation in a primary care setting and subsequent hospitalization risk. Dis Manag. 2004;7(4):325-332.
11. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care. 2000;23(3):390-404.
12. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial [published correction appears in JAMA. 1997;278(1):25]. JAMA. 1996;276(17):1409-1415.
13. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM, II: analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20(5):735-744.
14. Mollema ED, Snoek FJ, Pouwer F, Heine RJ, van der Ploeg HM. Diabetes Fear of Injecting and Self-Testing Questionnaire: a psychometric evaluation. Diabetes Care. 2000;23(6):765-769.
15. Peyrot M, Rubin RR, Lauritzen T, et al; the international DAWN advisory panel. Resistance to insulin therapy among patients and providers. Diabetes Care. 2005;28(11):2673-2679.
16. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract. 2007;77(1):1-15.
17. Anderson JH Jr, Brunelle RL, Koivisto VA, et al; Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46(2):265-270.
18. Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of longterm blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabetic Med. 2000;17(11):762-770.
19. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine [published correction appears in Endocr Pract. 2005;11(2):145]. Endocr Pract. 2005;11(1):11-17.
20. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA; U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000;23(5):639-643.
21. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basalbolus regimen. Clin Ther. 2004;26(5):724-736.
22. Hermansen K, Fontaine P, Kukolja K, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47(4):622-629.
23. Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med. 2006;23(3):285-292.
24. Riddle M, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086.
25. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [published correction appears in Diabetes Care. 2007;30(4):1035]. Diabetes Care. 2006;29(6):1269-1274.
26. Anderson JH Jr, Brunelle RL, Keohane P, et al; Multicenter Insulin Lispro Study Group. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non–insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157(11):1249-1255.
27. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu M. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes [published correction appears in Diabetes Res Clin Pract. 2006;72:112]. Diabetes Res Clin Pract. 2004;66(2):193-201.
28. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients [published correction appears in Diabet Med. 2002;19(9):797]. Diabet Med. 2002;19(5):393-399.
29. Roach P, Yue L, Arora V; Humalog Mix25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care. 1999;22(8):1258-1261.
30. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(suppl 3):S18-S24.
31. Hunt LM, Valenzuela M, Pugh J. NIDDM patients’ fears and hopes about insulin therapy. Diabetes Care. 1997;20(3):292-298. 32. Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005;29(3):186-192.
33. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543-2545.
34. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;(2):CD003287.
35. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD005613.
36. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7(1):56-64.
37. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007;9(3):209-217.
38. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19(7):31-41.
39. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, twoperiod crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848.
40. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data [published correction appears in Clin Ther. 2006;28(11):1968-1969]. Clin Ther. 2006;28(10):1712-1725.
41. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the insulin analogue insulin aspart on quality-of-life and treatment satisfaction in type 1 diabetic patients. Diabet Med. 2003;20(8):626-634.
42. Manini R, Forlani G, Moscatiello S, Zannoni C, Marzocchi R, Marchesini G. Insulin glargine improves glycemic control and healthrelated quality of life in type 1 diabetes. Nutr Metab Cardiovasc Dis. 2007;17(7):493-498.
43. Hanestad BR, Albrektsen G. Quality of life, perceived difficulties in adherence to a diabetes regimen, and blood glucose control. Diabet Med. 1991;8(8):759-764.
44. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart to buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25(3):439-444.
45. Raskin P, Holcombe JH, Tamborlane WV, et al. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications. 2001;15(6):295-300.
46. Valentine WJ, Palmer AJ, Erny-Albrecht KM, et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther. 2006;23(2):191-207.
47. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics. 2007;25(3):253-266.
48. McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin. 2007;23(suppl 1):7-19.
49. Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU. Costeffectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin. 2004;20(11):1729-1746.
50. Palmer AJ, Valentine WJ, Ray JA, et al. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Curr Med Res Opin. 2007;23(4):895-901.
51. Palmer AJ, Cobden D, Koenen C, et al. Projecting the economic and health outcome effects of basal insulin among type 2 patients in clinical practice settings [abstract]. Diabet Med. 2006;23(suppl 4):368.
52. Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Adv Ther. 2007;24(2):273-290.
53. McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin. 2007;23(suppl 1):21-31.
54. Lammert M, Palmer AJ, Roze S, et al. Decreased rates of major hypoglycemic events lead to improved long-term cost-effectiveness of biphasic insulin aspart 30/70 versus biphasic human insulin 30 in type 2 diabetic subjects in Danish, Finnish, German, Norwegian, Spanish, Swedish and UK settings [abstract]. Value Health. 2004;7(6):736.
55. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(suppl 1):S5-S26.
56. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(suppl 1):S27-S40.
57. Meneghini CF, Rosenberg KH, Koenen C, Merilainen MJ, Lilddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9(3):418-427.
58. Valentine W, Cobden D, Braceras R, et al. Health economic evaluation of improved glycemic control: initiating biphasic analog insulin [abstract]. Diabet Med. 2006;23(suppl 4):367.
59. Minshall M, Ray J, Lammert M, et al. Estimating the long-term cost-effectiveness of biphasic insulin aspart plus metformin versus optimization of oral hypoglycemic agents in insulin-naive patients with type 2 diabetes in a US cost setting [poster]. Diabetologia. 2005;48(suppl 1):A335.
60. Nicklasson L, Palmer AJ, Cobden D, et al. Long-term cost-effectiveness analysis of patients with type 2 diabetes mellitus inadequately controlled on thiazolidinedione therapy and either biphasic insulin aspart 30 or sulfonylurea [poster]. Diabetologia. 2005;48(suppl 1):A334.
61. Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin. 2005;21(2):291-298.
62. Bullano MF, Fisher MD, Grochulski WD, Menditto L, Willey VJ. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm. 2006;63(24):2473-2482.
63. Zhang Q, Menditto L. Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample. Am J Ther. 2005;12(4):337-343.
64. Orsini L, Huse DM. Total health care costs in Medicaid patients receiving NPH, Lente, or insulin glargine [abstract]. Diabetes. 2005;54(suppl 1):A144.
65. Miller DM, Gardner J, Hendricks A, Fincke G, Zhang Q. Changes in health care utilization and expenditures associated with insulin glargine use [abstract]. Diabetes. 2005;54(suppl 1):A302.
66. Ory C, Cyprien L, Menditto LA, Chang E. Health economic outcomes associated with insulin therapies: an evaluation of insulin glargine [abstract]. Diabetes. 2005;54(suppl 1):A612.
67. Hall JA, Summers KH, Obenchain RL. Cost and utilization comparisons among propensity score–matched insulin lispro and regular insulin users. J Manag Care Pharm. 2003;9(3):263-268.
68. Chen K, Chang EY, Summers KH, Obenchain RL, Yu-Isenberg KS, Sun P. Comparison of costs and utilization between users of insulin lispro versus users of regular insulin in a managed care setting. J Manag Care Pharm. 2005;11(5):376-382.
69. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29(3):554-559.
70. Botteman M, Cobden D, Nicklasson L. Cost to reach target HbA1c in poorly controlled patients with type 2 diabetes mellitus on either biphasic insulin aspart 30 and metformin or a maximized oral hypoglycemic regimen [poster]. Diabetologia. 2005;48(suppl 1):A334.
71. Ushakova O, Sokolovskaya V, Morozova A, et al. Biphasic insulin aspart 30 (NovoLog Mix 70/30), a premix analogue, is an effective and well tolerated starter insulin in type 2 diabetes [abstract]. Diabetes. 2005;54(suppl 1):A502.